La Jolla-based Ambrx announced the appointment of Dr. Yong-Jiang Hei as chief medical officer, reporting directly to CEO Tiecheng "Alex" Qiao.
With nearly 20 years of experience in pharmaceuticals and biotechnology, Hei brings knowledge and expertise in oncology clinical development as well as medical affairs. Prior to Ambrx, Hei worked at Amgen for more than nine years as an executive medical director in global development. He drove the design and execution of multiple clinical trials.
Hei also spent three years in China as the medical head for Amgen China. Before Amgen, Hei worked for Roche Laboratories Inc. and Novartis.
"We believe Yong-Jiang's leadership will be incredibly valuable as we plan to file New Drug Applications in Australia, New Zealand and China for ARX788, an antibody drug conjugate (ADC) that targets HER2 over-expressing tumors,” Qiao said in a statement. “Dr. Hei will play a key leadership role in guiding the company's future growth."
Ambrx is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code.